Complete financial analysis of Amylyx Pharmaceuticals, Inc. (AMLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amylyx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Electricity Generating Public Company Limited (EGCO-R.BK) Income Statement Analysis – Financial Results
- Covetrus, Inc. (CVET) Income Statement Analysis – Financial Results
- Oswal Greentech Limited (OSWALGREEN.BO) Income Statement Analysis – Financial Results
- Nippon Gas Co., Ltd. (8174.T) Income Statement Analysis – Financial Results
- Avarone Metals Inc. (AVRTF) Income Statement Analysis – Financial Results
Amylyx Pharmaceuticals, Inc. (AMLX)
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 380.79M | 22.23M | 285.00K | 650.00K | 1.43M |
| Cost of Revenue | 25.44M | 2.99M | 52.00K | 24.59M | 11.90M |
| Gross Profit | 355.35M | 19.24M | 233.00K | -23.94M | -10.47M |
| Gross Profit Ratio | 93.32% | 86.54% | 81.75% | -3,683.69% | -734.43% |
| Research & Development | 128.19M | 93.45M | 44.04M | 24.59M | 11.90M |
| General & Administrative | 178.86M | 127.13M | 38.93M | 15.06M | 3.08M |
| Selling & Marketing | 9.50M | 4.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 188.36M | 127.13M | 38.93M | 15.06M | 3.08M |
| Other Expenses | 0.00 | 3.74M | -285.00K | -650.00K | -1.43M |
| Operating Expenses | 316.54M | 220.58M | 82.69M | 39.01M | 13.55M |
| Cost & Expenses | 341.98M | 223.57M | 82.69M | 39.01M | 13.55M |
| Interest Income | 16.16M | 4.29M | 36.00K | 14.00K | 176.00K |
| Interest Expense | 0.00 | 4.29M | 0.00 | 2.29M | 1.28M |
| Depreciation & Amortization | 1.09M | 487.00K | 52.00K | 1.00K | 13.55M |
| EBITDA | 39.89M | -200.85M | -82.64M | -39.00M | 1.11M |
| EBITDA Ratio | 10.48% | -905.72% | -29,013.33% | -5,957.08% | -938.22% |
| Operating Income | 38.80M | -201.34M | -82.69M | -39.01M | -13.55M |
| Operating Income Ratio | 10.19% | -905.72% | -29,013.33% | -6,000.77% | -950.49% |
| Total Other Income/Expenses | 15.50M | 3.74M | -5.24M | -3.28M | -162.00K |
| Income Before Tax | 54.30M | -197.60M | -87.93M | -42.28M | -13.72M |
| Income Before Tax Ratio | 14.26% | -888.89% | -30,852.98% | -6,504.62% | -961.85% |
| Income Tax Expense | 5.03M | 774.00K | -52.00K | 2.56M | 1.10M |
| Net Income | 49.27M | -198.38M | -87.88M | -44.84M | -14.82M |
| Net Income Ratio | 12.94% | -892.38% | -30,834.74% | -6,898.00% | -1,038.99% |
| EPS | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| EPS Diluted | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| Weighted Avg Shares Out | 67.23M | 66.51M | 57.86M | 56.47M | 56.47M |
| Weighted Avg Shares Out (Dil) | 69.99M | 66.51M | 57.86M | 56.47M | 56.47M |
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia...
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference.
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy...
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James...
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024.
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,...
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in New York City: Morgan Stanley 22nd Annual Global Healthcare Conference:...
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2024 Earnings Call Transcript August 8, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - Co-Chief Executive Officer Camille...
Source: https://incomestatements.info
Category: Stock Reports